Differential Target Multiplexed Spinal Cord Stimulation (DETECT)

November 16, 2026 updated by: Moens Maarten

Differential Target Multiplexed Spinal Cord Stimulation: a Multicenter Cohort Study

Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

250

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Antwerp, Belgium
        • ZNA
      • Bruges, Belgium
        • AZ Sint-Jan Brugge-Oostende
      • Bruges, Belgium
        • AZ Sint-Lucas Brugge
      • Hasselt, Belgium
        • Jessa Ziekenhuis
      • Kortrijk, Belgium
        • AZ Groeninge
      • Leuven, Belgium
        • UZ Leuven
      • Lier, Belgium
        • Heilig Hart Ziekenhuis Lier
      • Liège, Belgium
        • Centre Hospitalier Régional (CHR) de la Citadelle
      • Mechelen, Belgium
        • AZ Sint-Maarten
      • Roeselare, Belgium
        • AZ Delta
      • Sint-Niklaas, Belgium
        • Vitaz
      • Turnhout, Belgium
        • AZ Turnhout
      • Wilrijk, Belgium
        • GZA
    • Brussels Capital
      • Jette, Brussels Capital, Belgium, 1090
        • Universitair Ziekenhuis Brussel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with chronic back and leg pain due to Failed Back Surgery Syndrome (FBSS)/Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.

Description

Inclusion Criteria:

  • Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
  • Age > 18 years
  • Patient has been informed of the study procedures and has given written informed consent
  • Patient willing to comply with study protocol including attending the study visits

Exclusion Criteria:

  • Expected inability of the patient to receive or properly operate the spinal cord stimulation system
  • History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
  • Active malignancy
  • Addiction to drugs, alcohol (>5 units per day) and/or medication
  • Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
  • Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
  • Life expectancy < 1 year
  • Local infection or any other skin disorder at site of incision
  • Pregnancy
  • Other implanted active medical device

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Spinal cord stimulation

Patients will receive differential target multiplexed spinal cord stimulation

differential target multiplexed stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall pain intensity with Visual Analogue Scale (VAS)
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm)

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Back pain intensity with Visual Analogue Scale (VAS)
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Leg pain intensity with Visual Analogue Scale (VAS)
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Clinical holistic responder status
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Proportion of successful DTM trials.
Time Frame: Evaluated after final SCS implantation
Evaluated after final SCS implantation
Battery consumption
Time Frame: Registration at 1 month, 6 months and 12 months of DTM SCS
Registration at 1 month, 6 months and 12 months of DTM SCS
Prevalence of technical issues with regard to DTM SCS programming
Time Frame: Throughout study period
Throughout study period
DTM SCS stimulation parameters
Time Frame: Registration at 1 month, 6 months and 12 months of DTM SCS
Registration at 1 month, 6 months and 12 months of DTM SCS
Pain medication use
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Open question regarding the dosage, frequency and type of pain medication

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Functional disability
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The functional disabilities will be assessed with the Oswestry Disability Index (ODI)

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Health related quality of life
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Patient global impression of change
Time Frame: Evaluated at 1 month, 6 months and 12 months of DTM SCS.

Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC).

Evaluated at 1 month, 6 months and 12 months of DTM SCS.
Patients' individual competencies for self-management
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health.

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Work status
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Work status is evaluated with a self-designed questionnaire

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Pain catastrophizing
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The Pain Catastrophizing Scale (PCS) will be used to measure the level of pain catastrophizing

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Symptoms of central sensitisation.
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The Central Sensitization Inventory is used to measure symptoms of central sensitisation

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Anxiety and Depression.
Time Frame: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression

The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
Healthcare utilisation.
Time Frame: The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS

Postoperative healthcare expenditure will be investigated by self-reporting methods.

The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
Time spent in body postures
Time Frame: The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months

Based on the AdaptiveStim technology, the time spent in body postures can be recorded.

The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
(Serious) adverse events
Time Frame: Throughout study period

Systematically recording all adverse events

Throughout study period
Patient expectations concerning SCS
Time Frame: Evaluated at baseline visit

Self-constructed open question to evaluate patient expectations about SCS

Evaluated at baseline visit

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 6, 2021

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

September 9, 2021

First Submitted That Met QC Criteria

September 26, 2021

First Posted (Actual)

October 5, 2021

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • DETECT

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.